Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-08-14 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-11 | Biosergen | Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-11 | Biosergen | Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-07 | Biosergen | Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Biosergen | Biosergen AB: Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-31 | Biosergen | Bulletin from the annual general meeting on 31 May 2023 in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Biosergen | Biosergen AB: Biosergen publishes 2022 annual report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Biosergen | Notice of annual general meeting in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Biosergen | Biosergen AB: Biosergen - Reduced risk after positive phase 1-studies - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Biosergen | Biosergen AB: Biosergen - Minskad risk efter positiva fas 1-studier - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for fourth quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-29 | Carlsquare | Carlsquare: Mrkt BUZZ, Biosergen: Plans for speedy development of lead candidate | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-29 | Biosergen | Biosergen AB: Biosergen provides Phase 2 clinical development strategy update | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-28 | Biosergen | Biosergen AB: Biosergen will be participating in Investerarträff arranged by Financial Stockholm, March 29 | Pressreleaser | Visa Stäng |
|
||||
2023-03-21 | Biosergen | Biosergen AB: Biosergen will be participating at Mangold Insight Investor Day, March 22 | Pressreleaser | Visa Stäng |
|
||||
2023-03-21 | Biosergen | Biosergen AB: Carlsquare has initiated its coverage of Biosergen | Pressreleaser | Visa Stäng |
|
||||
2023-03-20 | Carlsquare | Carlsquare: Initiation of coverage, Biosergen: Make antifungals great again | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-13 | Biosergen | Biosergen AB: Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-24 | Biosergen | Biosergen AB: Biosergen - Fungicide with potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-24 | Biosergen | Biosergen AB: Biosergen - Svampdödare med potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-16 | Biosergen | Biosergen AB: Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Biosergen AB: Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trialBSG005 is Biosergen’s lead development compound. It is a novel anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and difficult-to-treat fungal strains, which make them unique within all antifungal drug classes. The successful completion of the phase I trial will demonstrate, that BSG005 is a safe polyene anti-fungal compound with no impact on kidney function. The main short-coming of other polyenes are their severe side effects, such as nephrotoxicity. Breaking through this barrier makes BSG005 a candidate for first line therapy against severe invasive fungal infections. The clinical phase I trial is a double-blinded, placebo-controlled study in up to 72 healthy volunteers (subjects). The trial is designed as a Single Ascending Dose (SAD) study followed by a Multiple Ascending Dose (MAD) study to investigate the safety, tolerability and pharmacokinetics of BSG005. It is conducted in the Nucleus Network phase I Unit in Melbourne, Australia. The SAD part of the trial is completed and data are being analysed and will soon be ready for release. Biosergen’s CEO Peder M. Andersen comments: ”We are on a good track with our trial and are looking forward to go to the next dose level in the MAD part of the trial. If the trial continuous to show that BSG005 is well tolerated and that we can achieve what we believe are thereapeutic concentrations of the drug in the bloodstream of the subjects at safe doses, Biosergen will have taken a very significant step forward. I look forward to keeping you updated as the results come in.” Phase I study design The phase I study is divided into two sequential parts:
|
||||
2022-12-12 | Biosergen | Biosergen AB: The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-30 | Biosergen | Biosergen AB: Biosergen publishes interim report for third quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-10-20 | Biosergen | Biosergen AB: Biosergen's warrants of series TO2 are admitted to trading | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-19 | Biosergen | Biosergen AB: Biosergen allocates shares to an underwriter in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-05 | Biosergen | Biosergen AB: Biosergen appoints Mangold Fondkommission to act as a liquidity provider | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-04 | Biosergen | Biosergen AB: Biosergen announces the outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-26 | Biosergen | Biosergen AB: Mangold Insight publishes interview with Biosergen's CEO | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-22 | Biosergen | Biosergen AB: Members of the board of directors and executive management subscribe in ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-15 | Biosergen | Biosergen AB: The subscription period in Biosergen's rights issue starts today | Pressreleaser | Visa Stäng |
|
||||
2022-09-08 | Biosergen | Biosergen AB: Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-02 | Biosergen | Biosergen AB: Biosergen's Board of Directors decides on a rights issue of units of approximately SEK 60.2 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for second quarter 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-31 | Biosergen | Biosergen AB: Biosergen receives a loan of SEK 7 million to finance continued development | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Biosergen | Biosergen AB: Biosergen completes the third cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|